Literature DB >> 22550031

Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases.

Maria Stamelou1, Araceli Alonso-Canovas, Kailash P Bhatia.   

Abstract

Dystonia is considered one of the classical features of corticobasal degeneration and is reported in up to 83% in clinical, not pathologically confirmed, series. Here, we aimed to establish the frequency and the clinical characteristics of dystonia in CBD by reviewing the literature on 404 pathologically proven cases. Further, we aimed to identify the frequency and characteristics of dystonia in all described phenotypes with CBD pathology. Dystonia was present in only 37.5% of the 296 cases with adequate information. The majority of the cases with dystonia presented with a corticobasal syndrome, and dystonia occurred in the first 2 years from disease onset, affecting the upper limb. In cases with dystonia that presented with a "dementia" phenotype, dystonia tended to appear later in the disease course and to more affect the cervical region and the face. With regard to the distribution of the phenotypes, fifty-four percent of 374 cases presented as corticobasal syndrome, 15% as frontotemporal dementia, and 10.7% as progressive supranuclear palsy. Dystonia and myoclonus were present in about half of all cases with corticobasal syndrome, implying that these features may not be as frequent in corticobasal syndrome as are akinetic-rigid syndrome and apraxia (100% and 86.3%, respectively). Dystonia and myoclonus almost co-occurred in our analysis, suggesting a possible association. In conclusion, despite dystonia being an inclusion criterion in all sets of clinical criteria for corticobasal degeneration, this was present in only one third of the pathologically proven cases presented here. More accurate characterization of dystonia in corticobasal degeneration would be of importance for clinical diagnosis and development of treatment strategies.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22550031     DOI: 10.1002/mds.24992

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

2.  Asymmetric Limb Dystonia in Progressive Supranuclear Palsy: Conundrum in Nosology.

Authors:  Albert Stezin; Vikram V Holla; S P Chaithra; Nitish Kamble; Jitender Saini; Ravi Yadav; Pramod Kumar Pal
Journal:  Mov Disord Clin Pract       Date:  2019-04-05

3.  Corticobasal syndrome: Five new things.

Authors:  Lama M Chahine; Tanya Rebeiz; Jean J Rebeiz; Murray Grossman; Rachel G Gross
Journal:  Neurol Clin Pract       Date:  2014-08

Review 4.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

Review 5.  Parkinsonian syndromes.

Authors:  David R Williams; Irene Litvan
Journal:  Continuum (Minneap Minn)       Date:  2013-10

Review 6.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

7.  Perceptual decisions based on previously learned information are independent of dopaminergic tone.

Authors:  Alessandra Perugini; Michele A Basso
Journal:  J Neurophysiol       Date:  2017-11-22       Impact factor: 2.714

8.  Available and future treatments for atypical parkinsonism. A systematic review.

Authors:  Davide Vito Moretti
Journal:  CNS Neurosci Ther       Date:  2018-10-07       Impact factor: 5.243

9.  Stiff Limb Syndrome Mimicking Corticobasal Syndrome.

Authors:  Bettina Balint; Neil Mahant; Hans-Michael Meinck; Victor Fung
Journal:  Mov Disord Clin Pract       Date:  2014-10-28

Review 10.  Four-Repeat Tauopathies: Current Management and Future Treatments.

Authors:  Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.